Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphadenopathy » Immunoblastic Lymphadenopathy
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Immunoblastic Lymphadenopathy
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Immunoblastic Lymphadenopathy
Description
A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly. MeSH
Hierarchy View
Phase 3 Indicated Drugs (1)
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (48)
Cancer and Leukemia Group B (CALGB)
Case Western Reserve University
City of Hope National Medical Center
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Ospedale Maggiore Azienda Sanitaria Universitaria Trieste Ematologia
Organization Involved with Phase 1 Indications (19)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
